Boston Scientific Corp.
BSXHIGH VELOCITYFILING INTENSITYBoston Scientific Corp. reads as an High Velocity (composite 78/100); Sustained Capital Deployer deploying $8B across 5 disclosed transactions, running flat vs the prior cycle · primary market Life Sciences, ranked #3 on disclosed spend.
Lens
Disclosed M&A capital (2023–2025)
$8B
vs $8.2B in 2020–2022
Disclosed transactions
5
3/3 active fiscal years in window
Buyer archetype
Sustained Capital Deployer
Large disclosed acquisition spend recurs across many years.
Composite score
78
High Velocity dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $23.1B disclosed buyer spend
- Filed within 21d
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 21d
- 422 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- Control-process language
- 9 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 9 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 9 activism filings
- Latest activism 18y ago; heavily discounted
- Control-process filings
Distress Watch
Issuers showing financial-distress filing patterns
- 9 activism filings
Restatement Risk
Issuers with accounting-integrity flags from filings
Capital Velocity
DominantIssuers with the highest filing-activity intensity
- 422 8-Ks
- Filed within 21d
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $89.7B
- 10-Q 25d ago
- 4 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $4,640M · Peak count: 4
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | N/A | $1.6B | N/A | N/A |
| 2024 | 2 | $4.6B | $2.3B | N/A |
| 2023 | 3 | $1.8B | $604M | N/A |
| 2022 | 1 | $1.5B | $1.5B | N/A |
| 2021 | 4 | $2.3B | $565M | N/A |
| 2020 | N/A | $4.4B | N/A | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Technology Acquisition20%
- Bolt On20%
- Geographic Expansion20%
- Platform20%
- Horizontal Consolidation20%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- technology_acquisition
- bolt_on
- geographic_expansion
- platform
- horizontal_consolidation
- tuck_in
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“We believe that our products and solutions compete primarily on their ability to deliver both differentiated clinical and economic outcomes for our customers by enabling physicians to perform diagnostic and therapeutic procedures safely and effectively often in a less-invasive and cost effective manner.”
“We recognize that our continued competitive success will depend upon our ability to: •The effect of consolidation and competition in the markets in which we do business or plan to do business,”
“In the current environment of managed care, with economically motivated buyers, consolidation among health care providers, increasing prevalence and importance of regional and national tenders, increased competition and declining reimbursement rates, we are also required to compete on the basis of price, value, reliability and efficiency.”
“The medical device markets in which we participate are highly competitive.”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Life Sciences
- Market spend (2023–2025)
- $68.3B
- Market spend (2020–2022)
- $107.5B
- Recent vs prior
- −36%
- Issuer rank in market
- #3 of 155
- Share of market capital
- 6.0%
Valuation positioning
BSX trades at a +5.6-turn premium to the Life Sciences peer median of 13.2×.
- EV / Revenue
- 4.3×
- Net debt / EBITDA
- -0.3×
- Peer median EV / EBITDA
- 13.2×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
| 19.1× | 4.7× | -0.0× | $45.2B | $10.8B | |
Boston Scientific Corp.BSX | 18.8× | 4.3× | -0.3× | $20.6B | $8B |
| 13.3× | 3.5× | -0.1× | $35.5B | $2.2B | |
| 13.1× | 1.9× | -0.2× | $14.1B | $2.1B | |
| 8.5× | 1.8× | -0.0× | $16.6B | $3.3B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Life Sciences. Bars scaled to the highest EV/EBITDA in the set.
Target landscape.
Public-issuer targets that fit this buyer's archetype and target categories from filing-derived signal. Scores reflect cross-signal fit; reasons cite the EDGAR-anchored facts that drove the match.
No qualifying public-issuer targets surfaced from the current signal mix.
Stated target categories
No target categories enumerated in the audited corpus for this issuer.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)352026-02-17
- 10-Q (quarterly)962026-05-01
- 8-K (event)4222026-05-05
- Proxy / DEF 14A562026-03-18
- Activism (13D / DFAN / PREC)92008-04-25
Signals on file
- elevated
Activism on file
2008-04-259 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
- info
Signal
Recent transaction activity
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.